Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHANASDAQ:HCWBNASDAQ:RDHLNASDAQ:TXMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHAAthira Pharma$0.29+0.3%$0.27$0.22▼$3.67$11.24M3.041.48 million shs207,786 shsHCWBHCW Biologics$8.00$8.69$5.00▼$100.80$11.51M0.85259,725 shs57,332 shsRDHLRedHill Biopharma$1.80-2.2%$2.21$1.71▼$20.28$3.18M4.33163,347 shs12,962 shsTXMDTherapeuticsMD$1.45-2.7%$1.18$0.70▼$2.44$16.78M0.5156,104 shs20,396 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHAAthira Pharma+0.31%+7.23%-2.07%-31.87%-88.75%HCWBHCW Biologics0.00%-8.05%+5.61%-47.23%-81.82%RDHLRedHill Biopharma-2.17%-5.26%-17.05%-50.00%-99.37%TXMDTherapeuticsMD-2.68%-0.68%+18.85%+66.65%-34.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATHAAthira Pharma2.102 of 5 stars3.02.00.00.01.72.51.3HCWBHCW Biologics1.7899 of 5 stars0.05.00.00.03.33.30.0RDHLRedHill Biopharma0.5741 of 5 stars0.03.00.00.03.30.00.6TXMDTherapeuticsMD1.4484 of 5 stars0.05.00.00.02.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHAAthira Pharma 2.00Hold$13.834,704.91% UpsideHCWBHCW Biologics 0.00N/AN/AN/ARDHLRedHill Biopharma 0.00N/AN/AN/ATXMDTherapeuticsMD 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHAAthira PharmaN/AN/AN/AN/A$3.42 per shareN/AHCWBHCW Biologics$1.45M7.97N/AN/A$0.37 per share21.62RDHLRedHill Biopharma$8.04M0.40$180.00 per share0.01$40.58 per share0.04TXMDTherapeuticsMD$1.84M9.12N/AN/A$2.77 per share0.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHAAthira Pharma-$117.67M-$2.07N/AN/AN/AN/A-115.62%-88.94%7/30/2025 (Estimated)HCWBHCW Biologics-$24.99M-$23.25N/A∞N/A-1,067.82%-2,516.84%-132.95%N/ARDHLRedHill Biopharma$23.92MN/A0.00∞N/AN/AN/AN/A6/14/2025 (Estimated)TXMDTherapeuticsMD-$10.28MN/A0.00∞N/A-207.77%-14.08%-9.61%8/11/2025 (Estimated)Latest RDHL, TXMD, HCWB, and ATHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025HCWBHCW BiologicsN/A-$0.05N/A-$0.05N/AN/A5/13/2025Q1 2025TXMDTherapeuticsMDN/A-$0.06N/A-$0.06N/A$0.39 million5/9/2025Q1 2025ATHAAthira Pharma-$0.20-$0.23-$0.03-$0.23N/AN/A3/28/2025Q4 2024HCWBHCW BiologicsN/A-$3.20N/A-$0.08N/A$0.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHAAthira PharmaN/AN/AN/AN/AN/AHCWBHCW BiologicsN/AN/AN/AN/AN/ARDHLRedHill BiopharmaN/AN/AN/AN/AN/ATXMDTherapeuticsMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHAAthira PharmaN/A2.952.95HCWBHCW BiologicsN/A0.070.07RDHLRedHill BiopharmaN/A0.740.56TXMDTherapeuticsMDN/A2.032.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHAAthira Pharma57.12%HCWBHCW Biologics2.96%RDHLRedHill Biopharma7.20%TXMDTherapeuticsMD30.74%Insider OwnershipCompanyInsider OwnershipATHAAthira Pharma22.10%HCWBHCW Biologics49.90%RDHLRedHill Biopharma6.81%TXMDTherapeuticsMD2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHAAthira Pharma4039.04 million31.01 millionOptionableHCWBHCW Biologics401.44 million22.32 millionNot OptionableRDHLRedHill Biopharma2101.77 million1.19 millionNo DataTXMDTherapeuticsMD42011.57 million11.27 millionOptionableRDHL, TXMD, HCWB, and ATHA HeadlinesRecent News About These CompaniesStockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)May 22, 2025 | americanbankingnews.comTherapeuticsMD Announces First Quarter 2025 Financial ResultsMay 13, 2025 | businesswire.comTherapeuticsMD Inc. stock rises Monday, still underperforms marketMay 12, 2025 | marketwatch.comTherapeuticsMD Inc. stock outperforms competitors despite losses on the dayApril 8, 2025 | marketwatch.comTherapeuticsMD Announces Full Year 2024 Financial ResultsMarch 27, 2025 | businesswire.comTherapeuticsMD, Inc. (TXMD) Latest Press Releases & Corporate News - Yahoo FinanceMarch 26, 2025 | finance.yahoo.comTherapeuticsMD Inc’s Stock Drama: Could This Be a Game-Changer for TXMD Investors?January 7, 2025 | bovnews.comTherapeuticsMD Inc (TXMD) Stock: A Deeper Look at Its True PotentialJanuary 3, 2025 | bovnews.comTherapeuticsMD Inc. stock remains steady Friday, still outperforms marketDecember 27, 2024 | marketwatch.comTherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gainsNovember 23, 2024 | marketwatch.comTherapeuticsMD Shifts Focus with Lower Q3 LossesNovember 15, 2024 | markets.businessinsider.comTherapeuticsMD Reports Reduced Losses Amid Strategic ShiftNovember 15, 2024 | markets.businessinsider.comTherapeuticsMD Announces Third Quarter 2024 Financial ResultsNovember 13, 2024 | finance.yahoo.comTherapeuticsMD Inc. stock remains steady Monday, underperforms marketNovember 12, 2024 | marketwatch.comTherapeuticsMD (NASDAQ:TXMD) Stock, Option ChainNovember 6, 2024 | benzinga.comTherapeuticsMD Inc. stock remains steady Wednesday, underperforms marketNovember 6, 2024 | marketwatch.comTherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors despite daily gainsOctober 22, 2024 | marketwatch.comTherapeuticsMD Inc. stock remains steady Thursday, underperforms marketOctober 17, 2024 | marketwatch.comTherapeuticsMD Inc. stock remains steady Friday, underperforms marketOctober 11, 2024 | marketwatch.comTherapeuticsMD Inc. stock remains steady Thursday, still outperforms marketOctober 11, 2024 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRDHL, TXMD, HCWB, and ATHA Company DescriptionsAthira Pharma NASDAQ:ATHA$0.29 +0.00 (+0.31%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$0.29 +0.00 (+0.03%) As of 05/28/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.HCW Biologics NASDAQ:HCWB$8.00 0.00 (0.00%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$7.75 -0.25 (-3.08%) As of 05/28/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.RedHill Biopharma NASDAQ:RDHL$1.80 -0.04 (-2.17%) Closing price 05/28/2025 03:59 PM EasternExtended Trading$1.79 -0.01 (-0.33%) As of 05/28/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.TherapeuticsMD NASDAQ:TXMD$1.45 -0.04 (-2.68%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.46 +0.01 (+0.69%) As of 05/28/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
